Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1985 through 1987, worked at Inst of Med Enzymology, USSR Academy of Medical Sciences. From 1987 through 1989, was a senior Researcher, Koltzov Inst of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004, was being a Chairman of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. In 1993-1996, was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Dr Suchkov is a Co-Supervisor over the Russian-American Agreement on scientific and clinical collaboration in the field of ocular immunology between Russian Academy of Sciences and National Institutes of Health (NIH); in 1991-1995 – a member of The Reciprocal Exchange Fellowship Program between Russian Immunological Society and British Society for Immunology. Dr Suchkov is a member of the Editorial Boards of many international journals including EPMA Journal (Springer, Brussels) and “Personalized Medicine Universe” (Elsevier, Japan). Dr Sergey Suchkov, MD, PhD Director, Center for Personalized Medicine and Professor, Department of Pathology, Sechenov University, Chair, Department for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Professor, Dept for Immunology, A.I.Evdokimov Moscow State University of Medicine & Dentistry, Moscow, Russia Member, New York Academy of Sciences, NY, USA Secretary General, UCC (United Cultural Convention), Cambridge, UK Member, EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; Member, ISPM (International Society for Personalized Medicine), Tokyo, Japan; Member, PMC (Personalized Medicine Coalition), Washington, USA; Member, American Chemical Society (ACS), USA; Member, American Heart Association (AHA), USA; Secretary General, UCC (United Cultural Convention), Cambridge, UK
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM) to stimulate the development in a variety of clinical disciplines including Personalized and Precision Oncology (PPO). To achieve the implementation of PPO concept into the daily practice, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of cancer-associated bioindicators (biopredictors and biomarkers) of pre-cancer abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PPO on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the cancer patients and persons-at-risk resulting in improved outcomes whilst securing the healthy state and wellness, reduced adverse events, and more cost effective use of health care resources. Rapidly improving understanding of PPO, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. Deciding what therapy options to pursue can also be daunting, especially when tumors harbor more than one potentially actionable aberration. Further, different mutations/variants in a single gene may have different functional consequences, and response to targeted agents may be context dependent. However, early clinical trials with new molecular entities are increasingly conducted in a biomarker-selected fashion, and even when trials are not biomarker-selected, much effort is placed on enrolling patients onto clinical trials where they have the highest probability of response. Implementation of PPO requires a lot before the current model “oncologist-cancer patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPO to elicit the content of the new branch. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration.